Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Pens Drug-Repositioning Deal With Roche; Stands to Pocket Royalties, Milestones

NEW YORK, Dec. 8 (GenomeWeb News) - Gene Logic has penned a "drug-repositioning" alliance with Roche in an effort to help the Swiss drug giant identify alternative development paths for "multiple" candidate compounds, the company said today.

 

The Roche drugs Gene Logic will reevaluate under its Drug Repositioning Program have all passed Phase I human trials but were discontinued in Phase II or Phase III trials.

Gene Logic stands to receive success-based milestone payments for each drug candidate Roche returns to clinical development, and could pocket royalties for each marketed drug, the company said.

 

The agreement also gives Gene Logic the option to receive an exclusive license to any drug candidate that Roche chooses not to pursue. In this case, Roche, not Gene Logic, will receive success-based milestone and royalties.

The news comes three months after Gene Logic said it would help Pfizer, the world's biggest drug maker by revenue, reposition its stalled candidates.

Gene Logic's Drug Repositioning Program, which the company outlined in March, aims to find alternative development paths for drug candidates with good safety records that have been shelved by drug makers in Phase II or Phase III clinical trials.

 

Gene Logic said it can complete "initial repositioning testing and analysis" in less than a year and "potentially" return drug candidates "expediently" to clinical testing.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.